

# **Effect of a Glycine Residue Insertion into Crustacean Hyperglycemic Hormone on Hormonal Activity**

Authors: Katayama, Hidekazu, and Nagasawa, Hiromichi

Source: Zoological Science, 21(11) : 1121-1124

Published By: Zoological Society of Japan

URL: https://doi.org/10.2108/zsj.21.1121

BioOne Complete (complete.BioOne.org) is a full-text database of 200 subscribed and open-access titles in the biological, ecological, and environmental sciences published by nonprofit societies, associations, museums, institutions, and presses.

Your use of this PDF, the BioOne Complete website, and all posted and associated content indicates your acceptance of BioOne's Terms of Use, available at www.bioone.org/terms-of-use.

Usage of BioOne Complete content is strictly limited to personal, educational, and non - commercial use. Commercial inquiries or rights and permissions requests should be directed to the individual publisher as copyright holder.

BioOne sees sustainable scholarly publishing as an inherently collaborative enterprise connecting authors, nonprofit publishers, academic institutions, research libraries, and research funders in the common goal of maximizing access to critical research.

## **Effect of a Glycine Residue Insertion into Crustacean Hyperglycemic Hormone on Hormonal Activity**

Hidekazu Katayama<sup>†</sup> and Hiromichi Nagasawa\*

*Department of Applied Biological Chemistry, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Yayoi, Bunkyo, Tokyo 113-8657, Japan*

**ABSTRACT**—Crustacean hyperglycemic hormone (CHH) and molt-inhibiting hormone (MIH) have similar amino acid sequences and therefore comprise a peptide family referred to as the CHH family. All MIHs unexceptionally have an additional glycine residue at position 12, which is lacking in all CHHs. In order to understand the relevance of the absence of the glycine residue for hyperglycemic activity, a mutant CHH having a glycine residue insertion was prepared, and its hyperglycemic activity was assessed. This mutant CHH had the same disulfide bond arrangement as the recombinant CHH produced in *Escherichia coli* cells, and exhibited a similar circular dichroism spectrum to the recombinant CHH, indicating that the two CHHs possessed similar conformations. The mutant CHH showed a hyperglycemic effect weaker than the recombinant CHH by about one order of magnitude. These results suggest that the insertion of a glycine residue is one of the indices for structural and functional divergence of the CHH family peptides.

**Key words:** crustacean hyperglycemic hormone, kuruma prawn, mutational analysis

#### **INTRODUCTION**

In crustaceans, the hemolymph glucose level is regulated by crustacean hyperglycemic hormone (CHH). CHHs have been isolated from many crustacean species, and have amino acid sequences similar to that of molt-inhibiting hormones (MIHs). Therefore, CHHs and MIHs comprise a peptide family referred to as the CHH family (Keller, 1992). CHHs consist of 72 or 73 amino acid residues and have an amidated C-terminus. On the other hand, the C-terminus of most MIHs is not amidated, and a glycine residue is inserted at position 12.

The tertiary structure of MIH of the kuruma prawn *Marsupenaeus japonicus* has recently been determined (Katayama *et al*., 2003). The MIH carries five α-helices, and Gly $12$  is located in the short N-terminal helix. The tertiary structure of one of the *M. japonicus* CHHs was modeled based on the structure of the MIH. By comparison of tertiary and surface structures of MIH and CHH, the N-terminal helix of the MIH was presumed to be one of the significant regions for conferring biological activity (Katayama *et al*., 2003).

In the present study, in order to examine the signifi-

cance of the absence of a glycine residue at position 12 in natural CHHs, a mutant *M. japonicus* CHH (CHH-Gly12) with an additional glycine residue inserted between positions 11 and 12 was prepared, and its hyperglycemic activity was assessed.

#### **MATERIALS AND METHODS**

#### **Construction of an expression plasmid**

Cloning and characterization of a cDNA encoding Pej-SGP-I, one of the CHHs from *M. japonicus*, were reported previously (Ohira *et al*., 1997). Two primers, 12-F and 12-R, were designed based on the nucleotide sequence of Pej-SGP-I cDNA, with the inclusion of three nucleotides (GGT in 12-F, and ACC in 12-R, underlined in Table 1) encoding a glycine residue to be inserted at position 12. Two primers, F1 and R1, which completely matched the untranslated region of the cDNA were designed as forward and reverse primers, respectively. Another set of primers, F2 and R2, were designed to contain 20 nucleotide residues encoding the Nand C-terminal regions, respectively, and restriction enzyme sites (an *Nco* I site in F2, and an *Eco*R I site in R2, indicated by italics in Table 1). The nucleotide sequences of these primers are shown in Table 1. Three rounds of PCR were conducted. First, two rounds of PCR were separately conducted with two sets of primers, F1 and 12-R, and 12-F and R1, using a plasmid containing the Pej-SGP-I cDNA as template. Each PCR product was separated on a 2.0% agarose gel, and extracted from the gel using a kit of Quantum Prep Freeze'N Squeeze DNA Gel Extraction Spin Columns (Bio-Rad, USA) according to instructions of the manufacturer. Two PCR products thus obtained were mixed with PCR buffer, dNTP mixture and Taq polymerase. The mixture was allowed to react under the following program: 5 cycles of 30 sec at 94°C, 30 sec at 55°C, and 30

<sup>\*</sup> Corresponding author: Tel. +81-3-5841-5132; FAX. +81-3-5841-8022.

E-mail: anagahi@mail.ecc.u-tokyo.ac.jp † Present address: Institute for Protein Research, Osaka University,

Yamadaoka, Suita, Osaka 565-0871, Japan

**Table 1.** Nucleotide sequences of primers used in this study

Primer	Sequence
F1	CGTCCCTACGCTTTTACACT
F <sub>2</sub>	<i>CCATGG</i> CAAGCTTCATAGACAACACCTG
R <sub>1</sub>	GACAGCAGATTAGTGGGAAT
R <sub>2</sub>	GAATTCTCACTGTCCGGCGTTCAGGA
$12-F$	CGTCTTCGGTGACCGACAGCTCCTGCGAAG
12-R	TGTCGGTCACCGAAGACGCCAGTGCACGAA

*Italics* in F2 and R2 indicate the restriction enzyme recognition sequences. Nucleotide sequences encoding an additional glycine residue in 12-F and 12-R are underlined.

sec at 72°C. To this tube, a set of primers, F2 and R2, were added, and PCR was performed with the following program: 20 cycles of 30 sec at 94°C, 30 sec at 55°C, and 30 sec at 72°C. The amplified PCR product was cloned with a pCR2.1 plasmid (Invitrogen, USA), and the nucleotide sequence of the PCR product was analyzed. Subsequently, the insert was released from the pCR2.1 plasmid by digestion with *Nco* I/*Eco*R I, and then ligated into the *Nco* I/*Eco*R I site of an expression plasmid pProEX HTa (Invitrogen, USA).

## **Preparation of CHH-Gly<sup>12</sup>**

Expression, refolding reaction, cleavage of His-tag, amidating reaction and purification of CHH-Gly<sup>12</sup> were performed according to the method used for preparation of recombinant CHH (Katayama *et al*., 2002). The amidating enzyme was a kind gift from Drs. Ohsuye and Furukawa of Daiichi Suntory Pharma Co. Ltd., Japan.

#### **Bioassay for hyperglycemic activity**

Kuruma prawns, *M. japonicus*, were obtained at a fish market in Tokyo, Japan, and maintained in an aquarium at 20°C during the experiment. Hyperglycemic activity was assessed essentially according to the method described previously (Yang *et al*., 1995; Katayama *et al*., 2002).

#### **Trypsin digestion**

CHH-Gly<sup>12</sup> (15 µg) was dissolved in 300 µl of 25 mM HEPES buffer (pH 6.8). To this solution, 2 ul of TPCK-treated trypsin (Promega, USA) solution (1 mg/ml) was added, and the mixture was incubated at 37°C for 20 h. The digestion was stopped by the addition of 2 µl of trifluoroacetic acid (TFA). The tryptic digests were separated by reverse-phase HPLC (RP-HPLC) on a Capcell-Pak  $C_{18}$  column (2.0×250 mm, Shiseido, Japan) with a 30-min linear gradient of 0–40% acetonitrile in 0.05% TFA, and a 10-min linear gradient of 40–80% acetonitrile in 0.05% TFA at a flow rate of 0.2 ml/min.

#### **Amino acid sequence analysis**

The N-terminal amino acid sequences of peptides were analyzed on an Applied Biosystems model 476A protein sequencer in the pulsed-liquid mode. The phenylthiohydantoin derivative of cystine (PTH-cystine) was detected in amino acid sequencing using an Applied Biosystems model 492HT protein sequencer with a modified HPLC program (Katayama *et al.*, 2002).

#### **Mass spectral analysis**

Mass spectra were measured on a matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometer (Voyager-DE™ STR, Applied Biosystems, USA) with 3,5 dimethoxy-4-hydroxycinnamic acid or α-cyano-4-hydroxycinnamic acid as a matrix in the positive ion mode.

#### **Circular dichroism spectral analysis**

The recombinant peptide (about  $15 \mu g$ ) was dissolved in 250 µl of PBS. The circular dichroism (CD) spectrum was recorded from 200 to 260 nm on a spectropolarimeter (Jasco J-720, Japan) at room temperature with a 1-mm path length cell.

#### **RESULTS AND DISCUSSION**

## **Preparation of CHH-Gly12**

An expression plasmid containing the CHH-Gly $^{12}$  insert was constructed. Using this construct, CHH-Gly<sup>12</sup> was expressed as a fusion protein with an N-terminal histidine tag (His-tag). After breakage of the *E. coli* cells that expressed CHH-Gly $^{12}$ , the lysate was centrifuged to obtain soluble and insoluble fractions. These fractions were subjected to SDS-polyacrylamide gel electrophoresis, and a heavily stained band (≈11.5 kDa) likely representing CHH-Gly<sup>12</sup> was detected only in the insoluble fraction (Fig. 1), indicating that this peptide was expressed as inclusion bodies in *E. coli* cells. Since a refolding reaction was considered necessary for obtaining the mutant peptide in its natural conformation, it was performed according to the method used



**Fig. 1.** SDS-polyacrylamide gel electrophoresis (15% acrylamide) of soluble and insoluble fractions after cell breakage from a 0.1-ml culture. Lanes 1 and 2 are the soluble and insoluble fractions of cells carrying an expression vector containing the CHH-Gly<sup>12</sup> insert, respectively. The positions of molecular weight markers are indicated.

Peak No.	Retention time (min)	Sequence	Molecular ion peak, $m/z$ ((M+H) <sup>+</sup> )	
			observed	theoretical
	29.48	<b>VXDDXFNVFR</b>	4139.3	4139.2
		EPNVATEXR		
		<b>OXMAYVVPAHLHNEHR</b>		
2	33.15	<b>GAMGSLFDPSXTGVFGDR</b>	3029.5	3030.6
		<b>SNXYNNPVFR</b>		

**Table 2.** Amino acid sequence and TOF-MS analyses of tryptic fragments of CHH-Gly<sup>12</sup>.

X: Unidentified residue, but expected to be Cys.

for preparation of recombinant CHH (Katayama *et al*., 2002). Subsequently, a His-tag attached at the N-terminus of CHH-Gly $^{12}$  was removed by digestion with TEV protease. CHH-Gly<sup>12</sup> was amidated with peptidylglycine  $\alpha$ -amidating enzyme, and the resulting peptide was purified by RP-HPLC. The peptide showed an expected single molecular ion peak at *m/z* 8751.3 and an expected N-terminal sequence, Gly-Ala-Met-Gly-Ser-Leu-Phe-Asp-Pro-Ser-, which was identical to that of natural CHH except for the four Nterminal residues derived from the nucleotide sequence of the expression plasmid. Since the recombinant CHH having four additional residues at the N-terminus showed hyperglycemic activity as high as the natural peptide (Katayama *et al*., 2002), it was unlikely that these four residues in CHH- $\text{Gly}^{12}$  affected hormonal activity.

In order to examine whether the recombinant peptide possessed natural conformation, we analyzed the arrangement of disulfide bonds in CHH-Gly $<sup>12</sup>$  by identification of its</sup> tryptic digests, as was done for the recombinant CHH (Katayama *et al*., 2002). Two major peaks were observed in the elution profile of tryptic digests of CHH-Gly<sup>12</sup> on RP-HPLC. Table 2 shows the results of mass spectral and amino acid sequence analyses. Fragment 2 contained one disulfide bond between  $\text{Cys}^7$  and  $\text{Cys}^{44}$ . In the amino acid sequence analysis of fragment 1, PTH-cystine was detected at both cycles 5 and 8, unambiguously establishing the two disulfide bonds between  $Cys^{24}$  and  $Cys^{40}$ , and between  $Cys<sup>27</sup>$  and  $Cys<sup>53</sup>$ . This disulfide bond arrangement was identical to that of the recombinant CHH (Katayama *et al*., 2002). The circular dichroism (CD) spectrum of CHH-Gly<sup>12</sup> exhibited a pattern typical for  $\alpha$ -helix-rich proteins (data not shown), and it was calculated that the  $\alpha$ -helix content in CHH-Gly<sup>12</sup> was 44.7%. These results were similar to those of the natural and recombinant CHHs (Katayama *et al*., 2002). All these results indicate that CHH-Gly<sup>12</sup> possesses a conformation similar to the conformations of natural and recombinant CHHs.

### **Biological activity of CHH-Gly12**

The dose-response relationship of CHH-Gly<sup>12</sup> in hyperglycemic activity is shown in Fig. 2. Injection of 100 pmol of  $CHH-GIv<sup>12</sup>$  increased the hemolymph glucose levels slightly, and its hyperglycemic activity reached a maximum at 300 pmol. It was demonstrated that the recombinant CHH



Fig. 2. (A) Dose-response relationship of CHH-Gly<sup>12</sup>. (B) Negative control, injection of PBS; positive control, injection of sinus gland extract (one sinus gland equivalent) of *M. japonicus*. Results are expressed as the mean±S.E. (*N*=7–14). Asterisks indicate values significantly different from the negative control. Symbols, (\*) and (\*\*), indicate *P*<0.01 and *P*<0.001, respectively, which were calculated with the program of Fishers PLSD.

showed low hyperglycemic activity at 10 pmol and high activity at 100 pmol (Katayama *et al.*, 2002). These results indicated that the hyperglycemic activity of CHH-Gly $^{12}$  was lower than that of the recombinant CHH by about one order of magnitude.

In the tertiary structure of *M. japonicus* MIH, the Gly<sup>12</sup> residue is positioned in the short N-terminal helix, and it was presumed that this helical structure might be lost by the absence of the Gly12 residue (Katayama *et al*., 2003). Comparison of the tertiary and surface structures of the MIH with those of the modeled CHH suggests that this N-terminal helix is one of the significant regions for conferring MIH activity, and therefore the glycine residue at position 12 is likely to be one of the indices for diversification of the functions of the CHH family peptides. Thus, the present results are consistent with the hypothesis on the structure-activity relationship of the CHH family peptides.

The mutational analysis of *M. japonicus* MIH demonstrated that the residues at positions 13, 14, 71 and 72 were significant for conferring molt-inhibiting activity (Katayama *et al.*, 2004). It was presumed that these residues were some of indices of dividing the functions of CHH-family peptides,

and were not conserved between CHHs and MIHs. Therefore, it is likely that CHH-Gly<sup>12</sup> could not show the moltinhibiting activity, and additional mutations at these positions would be required for exhibiting the molt-inhibiting activity.

Recently, it was proposed that molecular evolution of the CHH family peptides was similar to that of the growth hormone (GH) family proteins including GH and prolactin (PRL) (Chan *et al*., 2003); GH and PRL are structurally similar but functionally completely different. This is also true for the CHH family, but there are some exceptions; CHH of the lobster *Homarus americanus* showed both CHH and MIH activity (Chang *et al*., 1990). Therefore, it is likely that the CHH family peptides may be still on their way to attaining complete functional diversity. Studies on structural differences between CHH and MIH receptors and molecular mechanism of hormone-receptor interaction are required for revealing the significance of the glycine residue insertion or deletion in the functional and structural diversion.

#### **ACKNOWLEDGEMENTS**

We are grateful to Drs. K. Ohsuye and K. Furukawa of Daiichi Suntory Pharma Co. Ltd., Japan for supplying us with the amidating enzyme. We also thank Dr. V. Jayasankar of Japan International Research Center for Agricultural Science for critical reading of this manuscript. This work was partly supported by a Grant-in-Aid for Scientific Research (No. 15208011) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The first author (H.K.) is supported by a Research Fellowship of the Japan Society for the Promotion of Science for Young Scientists.

#### **REFERENCES**

- Chan SM, Gu PL, Chu KH, Tobe SS (2003) Crustacean neuropeptide genes of the CHH/MIH/GIH family: implications from molecular studies. Gen Comp Endocrinol 134: 214–219
- Chang ES, Prestwich GD, Bruce MJ (1990) Amino acid sequence of a peptide with both molt-inhibiting and hyperglycemic activities in the lobster, *Homarus americanus*. Biochem Biophys Res Commun 171: 818–826
- Katayama H, Ohira T, Aida K, Nagasawa H (2002) Significance of a carboxyl-terminal amide moiety in the folding and biological activity of crustacean hyperglycemic hormone. Peptides 23: 1537–1546
- Katayama H, Nagata K, Ohira T, Yumoto F, Tanokura M, Nagasawa H (2003) The solution structure of molt-inhibiting hormone from the kuruma prawn *Marsupenaeus japonicus*. J Biol Chem 278: 9620–9623
- Katayama H, Ohira T, Nagata S, Nagasawa H (2004) Structureactivity relationship of crustacean molt-inhibiting hormone from the kuruma prawn *Marsupenaeus japonicus*. Biochemistry 43: 9629–9635
- Keller R (1992) Crustacean neuropeptides: Structures, functions and comparative aspects. Experientia 48: 439–448
- Ohira T, Watanabe T, Nagasawa H, Aida K (1997) Molecular cloning of cDNAs encoding four crustacean hyperglycemic hormones and a molt-inhibiting hormone from the Kuruma prawn *Penaeus japonicus*. In "Proceedings of the XIII International Congress of Comparative Endocrinology" Ed by S Kawashima and S Kikuyama, Monduzzi Ediore, Bologna, Italy, pp 83–86
- Yang W-J, Aida K, Nagasawa H (1995) Amino acid sequences of a hyperglycaemic hormone and its related peptides from the Kuruma prawn, *Penaeus japonicus*. Aquaculture 135: 205–212

(Received July 5, 2004 / Accepted August 21, 2004)